InnoCare Turns Profitable Two Years Early, Boosted by 43% Sales Growth

Edgen Stock

·Mar 30 2026, 07:36

Share to

Share to

Copy link

Key Takeaways

InnoCare Pharma (09969.HK) achieved its first full-year profit in 2025, two years ahead of schedule, driven by strong drug sales and a landmark licensing deal. The financial turnaround prompted Goldman Sachs to raise its price target, signaling confidence in the company's improved operational leverage and growth strategy.

Early Profitability: The company reported a RMB642 million net profit for 2025, marking a significant reversal from a loss and achieving its break-even goal two years ahead of analyst forecasts.
Revenue Surge: Total drug sales climbed 43.4% year-over-year to RMB 1,442 million, bolstered by RMB837 million in collaboration revenue from a licensing deal with Zenas potentially worth over $2 billion.
Analyst Upgrade: Goldman Sachs maintained its "Buy" rating and increased its price target to HKD19.93, underscoring the company's robust profit structure despite projections for higher R&D expenses.

Licensing Deal Propels InnoCare to RMB642M Profit Two Years Early

InnoCare Pharma (09969.HK) achieved its first-ever annual profit in 2025, reporting net earnings of RMB642 million and reaching profitability two years ahead of expectations. The milestone was driven by a 43.4% year-over-year increase in drug sales to RMB 1,442 million, combined with significant income from strategic partnerships.

A key contributor was a transformative licensing agreement with Zenas for the autoimmune pipeline, including the drug orelabrutinib. The deal, which has a total value potentially exceeding $2 billion, provided approximately RMB837 million in collaboration revenue during the fourth quarter, including up to $100 million in upfront and near-term milestone payments. This partnership is set to accelerate the global Phase III development of orelabrutinib for multiple sclerosis.

Orelabrutinib Sales Hit RMB390M in Q4 as Reimbursement Expands

The company's core product, Orelabrutinib, generated RMB390 million in sales in the fourth quarter of 2025, a 27% increase from the prior year. Growth was supported by its successful inclusion in China's updated National Reimbursement Drug List (NRDL) for all four of its approved indications, enhancing market access and affordability for lymphoma patients.

Following the results, Goldman Sachs reiterated its "Buy" rating on InnoCare and raised its price target from HKD19.91 to HKD19.93. While the firm slightly lowered its net profit forecasts for 2026-2028 to reflect higher planned research and development expenses, it noted that InnoCare's operational leverage has improved. Company management expressed confidence in maintaining profitability through 2027 even without new business development deals.